Title |
Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment
|
---|---|
Published in |
BMC Infectious Diseases, January 2015
|
DOI | 10.1186/s12879-015-0754-x |
Pubmed ID | |
Authors |
Hoang Van Tong, Le Huu Song, Nghiem Xuan Hoan, Bui Khac Cuong, Bui Tien Sy, Ho Anh Son, Do Quyet, Vu Quoc Binh, Peter G Kremsner, Claus Thomas Bock, Thirumalaisamy P Velavan, Nguyen Linh Toan |
Abstract |
BackgroundThe human major histocompatibility complex class I polypeptide-related sequence B (MICB) is a protein that modulates the NK and T cell activation through the NKG2D receptor and is related to several diseases including cancer.MethodsThe study investigated the prognostic role of soluble MICB (sMICB) protein in the progression of HBV-related liver diseases and to HBV-related HCC treatment. The sMICB serum levels were measured in 266 chronic HBV-infected Vietnamese patients and in healthy controls, and correlated with clinical and laboratory parameters and with therapeutic interventions for HBV-related HCC.ResultsSignificant differences in both clinical and laboratory parameters were observed among the patient groups with different stages of hepatitis. The platelet counts were significantly decreased with disease progression (P¿<¿0.001). The sMICB serum levels were significantly increased in HBV patients compared to healthy controls (P¿<¿0.0001). Among the patients with different stages of hepatitis, asymptomatic individuals (ASYM) revealed higher sMICB serum levels while liver cirrhosis (LC) patients revealed lower sMICB serum levels (P¿<¿0.0001) compared to other patient groups. Notably, the sMICB serum levels were decreased in treated HCC patient group compared to not-treated HCC patient group (P¿=¿0.05). Additionally, the sMICB levels were significantly correlated with platelet counts in ASYM and HCC patients (r¿=¿¿0.37, P¿=¿0.009; and r¿=¿0.22, P¿=¿0.025, respectively).ConclusionsOur results demonstrate a potential role of sMICB serum levels and platelet counts during immune response to the HBV infection, liver disease progression and response to the HCC treatment. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 24 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 4 | 17% |
Student > Master | 4 | 17% |
Researcher | 4 | 17% |
Student > Ph. D. Student | 3 | 13% |
Student > Doctoral Student | 2 | 8% |
Other | 3 | 13% |
Unknown | 4 | 17% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 33% |
Biochemistry, Genetics and Molecular Biology | 2 | 8% |
Agricultural and Biological Sciences | 2 | 8% |
Immunology and Microbiology | 2 | 8% |
Nursing and Health Professions | 1 | 4% |
Other | 4 | 17% |
Unknown | 5 | 21% |